Future Market Insights’ updated report predicts the global postmenopausal osteoporosis treatment market size to reach US$ 13.1 billion in 2024. Global postmenopausal osteoporosis treatment demand is anticipated to surge at a 5.8% CAGR, guiding total market valuation to reach a staggering US$ 23.0 billion by 2034.
Bisphosphonates remain the first line of treatment for postmenopausal osteoporosis owing to their higher efficacy and low cost. Patients are increasingly consuming these medications to manage osteoporosis and its symptoms. The target segment is set to rise at 5.6% CAGR.
Future Outlook for Postmenopausal Osteoporosis Treatment Market:
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | US$ 12.3 billion |
| Market Size in 2024 | US$ 13.1 billion |
| Market Revenue in 2034 | US$ 23.0 billion |
| Value-based CAGR (2024 to 2034) | 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Postmenopausal osteoporosis is becoming a common health condition in women after menopause when estrogen levels decline. It causes bones to become weak and brittle, necessitating effective treatment approaches like osteoporosis drugs.
Women with postmenopausal osteoporosis are increasingly consuming medications like bisphosphonates to manage the condition. This is providing impetus for the growth of the postmenopausal osteoporosis therapeutics market.
According to the World Health Organization (WHO), the world population aged 60 and above is projected to reach around 2.1 million by 2050. This will fuel demand for postmenopausal osteoporosis medications as older people are more prone to osteoporosis.
Patients are increasingly consuming oral medications for postmenopausal osteoporosis due to their low cost and high effectiveness. High spending on these medications is anticipated to boost sales growth in the market. To benefit from this, new oral agents like selective receptor modulators (SERMs) and cathepsin K inhibitors are being developed by companies.
Availability of various drugs for postmenopausal osteoporosis treatment is projected to boost sales growth. Both patients and healthcare professionals choose a specific drug type based on its efficacy and cost. Many new non-hormonal osteoporosis treatments for postmenopausal women are making their way into the market.
Escalating emphasis on bone health and preventive measures to reduce the risk of osteoporosis is encouraging people to consume calcium, Vitamin D, and other medications. This will positively impact postmenopausal osteoporosis medication sales through 2034.
Key players are striving to develop cost-effective treatment options for postmenopausal osteoporosis. This will make osteoporosis management affordable and accessible to general public.
On the other hand, side effects of postmenopausal osteoporosis medications are anticipated to limit market growth. Bisphosphonate drugs like risedronate and alendronate often cause nausea, heartburn, and vomiting, demotivating patients to consume them.
Although hormone replacement therapy for postmenopausal osteoporosis can effectively reduce bone loss and relieve other symptoms, it can increase the risk of stroke, blood clots, and breast cancer. These side effects are believed to limit growth of the target industry.
Global postmenopausal osteoporosis treatment demand grew at a healthy CAGR of 7.5% during the historical period, with total market valuation reaching US$ 12.3 billion in 2023. In the next ten years, a CAGR of 5.8% has been predicted for the target industry, depicting a deduction of 1.7% CAGR from the historical period.
Multiple factors are anticipated to stimulate growth of the postmenopausal osteoporosis drug market during the forecast period. These include growing awareness of osteoporosis and its treatments, introduction of novel drug candidates, and favorable government support.
To gain maximum benefits, key players are concentrating on developing new biopharmaceuticals like monoclonal antibodies. Similarly, high efficacy of hormone replacement therapies is encouraging their popularity and adoption among patients.
Many companies are also looking to develop injectable treatments for postmenopausal osteoporosis. This will positively impact market growth during the assessment period.
Principal Consultant
High Prevalence of Osteoporosis among Older Women
One of the prominent factors dictating growth of the postmenopausal osteoporosis therapeutics market is the increasing incidence of osteoporosis in women going through menopause. These women have low levels of estrogen, resulting in a decrease in bone density and high risk of fractures.
In order to treat postmenopausal osteoporosis and reduce the risk of fractures, patients opt for medications like bisphosphonates. This, in turn, is anticipated to fuel sales of postmenopausal osteoporosis drugs and boost market growth.
Increasing Diagnostic Rates
Osteoporosis is becoming a serious health issue due to its devastating effects on the human body. As a result, diagnosing and treating this medical condition becomes necessary, prompting people to opt for various diagnostic tests and treatments.
New diagnostic techniques like bone density scans (DEXA scans) are allowing for earlier detection of osteoporosis. Thus, rising diagnostic rates of osteoporosis will eventually lead to higher demand for postmenopausal osteoporosis drugs through 2034.
The section below comprehensively evaluates three interrelated markets: the global postmenopausal osteoporosis medication industry, the menopause treatment market, and the osteonecrosis treatment industry. It dissects each market's distinctive characteristics, encompassing their respective CAGRs, while delving into the pivotal factors influencing their growth trajectories.
Global Postmenopausal Osteoporosis Treatment Market Analysis:
| Attribute | Global Postmenopausal Osteoporosis Treatment Market Forecast |
|---|---|
| CAGR (2024 to 2034) | 5.8% |
| Growth Factor | Escalating prevalence of osteoporosis among elderly women is providing impetus for market growth. |
| Key Trends in Postmenopausal Osteoporosis Treatment Market | Key growth shaping trends include development of new biologic therapies for postmenopausal osteoporosis, growing interest in personalized medicine, and surging adoption of digital health solutions like wearable devices and mobile apps to improve patient engagement and adherence in osteoporosis management. |
Global Menopause Treatment Market Forecast:
| Attribute | Global Menopause Treatment Industry Outlook |
|---|---|
| CAGR (2024 to 2034) | 5.6% |
| Growth Factor | Increasing prevalence of post-menopausal syndrome is a prominent factor boosting growth of the menopause treatment market. |
| Key Trends | Growing acceptance of menopause treatments due to growing health awareness will benefit the market. |
Global Osteonecrosis Treatment Market Analysis:
| Attribute | Global Osteonecrosis Treatment Industry Outlook |
|---|---|
| CAGR (2024 to 2034) | 4.9% |
| Growth Factor | Surging geriatric population and increasing incidence of osteonecrosis are fueling market growth. |
| Key Trends | Development of novel osteonecrosis drugs and growing preference for non-invasive treatments are key trends influencing sales growth. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below shows the estimated growth rates of the top key countries. South Korea and Japan are set to record high CAGRs of 8.0% and 7.3%, respectively, through 2034.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 5.9% |
| United Kingdom | 6.7% |
| China | 6.6% |
| Japan | 7.3% |
| South Korea | 8.0% |
The table below highlights key countries’ market revenues. The United States and China are forecast to remain the top consumers of postmenopausal osteoporosis medications, with predicted valuations of US$ 4.0 billion and US$ 3.6 billion, respectively, in 2034.
| Countries | Market Revenue (2034) |
|---|---|
| United States | US$ 4.0 billion |
| United Kingdom | US$ 929.0 million |
| China | US$ 3.6 billion |
| Japan | US$ 2.5 billion |
| South Korea | US$ 1.5 billion |
The United States postmenopausal osteoporosis treatment market is forecast to exhibit a CAGR of 5.9% during the next decade, totaling a staggering valuation of US$ 4.0 billion by 2034. This is attributable to surging incidence of osteoporosis in the nation as well as availability of favorable reimbursement policies for postmenopausal osteoporosis treatment.
According to the Bone Health & Osteoporosis Foundation (BHOF), around 10 million Americans have osteoporosis, with incidence greater in women. This high prevalence is creating demand for postmenopausal osteoporosis medications in the nations, and the trend will persist through 2034.
Rise in early osteoporosis diagnosis is another key factor propelling demand for osteoporosis drugs. Similarly, strong presence of leading pharmaceutical and biopharmaceutical giants is improving the United States market share.
The United States is home to several top biopharmaceutical companies, including Amgen. These companies are constantly striving to develop novel and effective medications for osteoporosis treatment.
FMI’s latest analysis estimates China's postmenopausal osteoporosis industry value to total US$ 3.6 billion by 2034, registering a CAGR of 6.6% throughout the forecast period. This is due to China’s rapidly increasing geriatric population, favorable government support, and ongoing new drug launches.
China is witnessing a spike in the geriatric population, which will majorly guide postmenopausal osteoporosis drug shipments throughout the forecast period. Older women are more prone to postmenopausal osteoporosis, prompting them to opt for various treatments.
Rising healthcare expenditure and surging awareness about postmenopausal osteoporosis are also sculpting postmenopausal osteoporosis therapeutic market growth in China. High healthcare spending by the Chinese government to make osteoporosis treatments affordable and accessible to the general public will bode well for the market.
The section below provides deeper insights into top segments and their respective values & shares in the global market. This information can help companies act accordingly and strengthen their presence in lucrative regions.
Based on drug type, the bisphosphonates segment is poised to grow at 5.6% CAGR through 2034. By distribution channel, the hospital pharmacies category will record a CAGR of 5.4% from 2024 to 2034.
| Top Segment | Bisphosphonates (Drug Type) |
|---|---|
| CAGR (2024 to 2034) | 5.6% |
Bisphosphonates remain the most preferred drugs for treating postmenopausal osteoporosis. This can be attributed to high adoption of bisphosphonates for postmenopausal osteoporosis due to their higher efficacy in reducing the risk of bone loss. The latest analysis estimates bisphosphonates demand to soar at 5.6% CAGR through 2034.
Bisphosphonates such as alendronate and risedronate are the first line of treatment for women at high risk of osteoporosis fractures. These medications effectively treat postmenopausal osteoporosis by reducing the rate of bone loss.
Escalating demand for targeted therapeutics and a shift in prescribing patterns towards bisphosphonates are anticipated to boost segment growth. Bisphosphonates work by slowing down bone breakdown and improving bone density.
Bisphosphonates are effective in treating various solid tumors affecting bones, such as multiple myeloma, by reducing skeletal morbidity. These medications are increasingly being used in combination with anticancer therapies to prevent skeletal problems and alleviate bone pain.
Although bisphosphonates currently dominate the market, emerging trends suggest a transition towards more contemporary precision-targeted therapies and biopharmaceuticals. For instance, hormone replacement therapy is becoming a top contender in postmenopausal osteoporosis management.
Many patients are choosing hormone replacement therapy for postmenopausal osteoporosis due to its promising results. As a result, a rapid CAGR has been predicted for the target segment between 2024 and 2034.
| Top Segment | Hospital Pharmacies (Distribution Channel) |
|---|---|
| CAGR (2024 to 2034) | 5.4% |
Based on distribution channel, hospital pharmacies held 42.0% of the postmenopausal osteoporosis treatment market share in 2023. Over the next ten years, the target segment is forecast to record a CAGR of 5.4%.
Hospital pharmacies are centralized distribution channels for medication procurement, storage, dispensing, and management within healthcare institutions. They dispense postmenopausal osteoporosis medications to patients undergoing treatments in hospitals.
Leading manufacturers of postmenopausal osteoporosis drugs are rigorously investing in research and development to introduce novel therapies for postmenopausal osteoporosis with improved efficacy and fewer side effects. They are investigating biologics that target specific pathways involved in bone loss.
Companies are also striving to get fast-track approvals for their new drugs. Similarly, the market is witnessing strategies like partnerships, distribution agreements, collaborations, mergers, and acquisitions as players look to strengthen their presence and improve their market shares.
Key Players in the Postmenopausal Osteoporosis Treatment Market:
Recent Developments:
The global market is estimated to be valued at US$ 13.1 billion in 2024.
Global demand is poised to grow at a CAGR of 5.8% through 2034.
By 2034, the global market size is set to reach US$ 23.0 billion.
The target industry registered a CAGR of 7.5% from 2019 to 2023.
The United States is poised to record a CAGR of 5.9% through 2034.
Bisphosphonates.
The FDA recently approved romosozumab for osteoporosis in postmenopausal women.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Manufacturer
3.5.1.2. Mid-Level Participants (Traders)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ billion) & Volume (Unit Pack) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis By Drug Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ billion) & Volume (Unit Pack) Analysis and Forecast By Drug Type, 2024 to 2034
5.3.1. Bisphosphonates
5.3.2. Vitamin D3
5.3.3. Estrogen Agonist/Antagonist
5.3.4. Hormone Replacement Therapy
5.3.5. Parathyroid Hormone Therapy
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Drug Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023
6.3. Current and Future Market Size Value (US$ billion) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
7.3. Current Market Size Value (US$ billion) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
8.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
8.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
8.2.1. By Country
8.2.1.1. United States
8.2.1.2. Canada
8.2.2. By Drug Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Drug Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Drug Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Drug Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of Middle East & Africa
14.2.2. By Drug Type
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. United States
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2024
15.1.2.1. By Drug Type
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2024
15.2.2.1. By Drug Type
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2024
15.3.2.1. By Drug Type
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2024
15.4.2.1. By Drug Type
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2024
15.5.2.1. By Drug Type
15.5.2.2. By Distribution Channel
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2024
15.6.2.1. By Drug Type
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2024
15.7.2.1. By Drug Type
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2024
15.8.2.1. By Drug Type
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2024
15.9.2.1. By Drug Type
15.9.2.2. By Distribution Channel
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2024
15.10.2.1. By Drug Type
15.10.2.2. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2024
15.11.2.1. By Drug Type
15.11.2.2. By Distribution Channel
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2024
15.12.2.1. By Drug Type
15.12.2.2. By Distribution Channel
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2024
15.13.2.1. By Drug Type
15.13.2.2. By Distribution Channel
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2024
15.14.2.1. By Drug Type
15.14.2.2. By Distribution Channel
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2024
15.15.2.1. By Drug Type
15.15.2.2. By Distribution Channel
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2024
15.16.2.1. By Drug Type
15.16.2.2. By Distribution Channel
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2024
15.17.2.1. By Drug Type
15.17.2.2. By Distribution Channel
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2024
15.18.2.1. By Drug Type
15.18.2.2. By Distribution Channel
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2024
15.19.2.1. By Drug Type
15.19.2.2. By Distribution Channel
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2024
15.20.2.1. By Drug Type
15.20.2.2. By Distribution Channel
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2024
15.21.2.1. By Drug Type
15.21.2.2. By Distribution Channel
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2024
15.22.2.1. By Drug Type
15.22.2.2. By Distribution Channel
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2024
15.23.2.1. By Drug Type
15.23.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Type
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Amgen Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Eli Lilly and Company
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Novartis International AG
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Gilead Sciences, Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Teva Pharmaceutical Industries Ltd.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Merck & Co., Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Pfizer Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. GlaxoSmithKline plc
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Roche Holding AG
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Johnson & Johnson
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Postmenopausal Osteoporosis Treatment Market
